Hofseth BioCare Q2 FY26 EBIT loss narrows to NOK 12.9 million; revenue falls 3.95% to NOK 65.7 million
Reuters2026/08/21 06:15- Hofseth BioCare Q2 2026 revenue slipped 3.95% to NOK 65.7 million.
- EBITDA loss narrowed to NOK 2.7 million from NOK 5.4 million a year earlier.
- EBIT loss improved to NOK 12.9 million from NOK 14.9 million a year earlier.
- Cash climbed NOK 59.7 million to NOK 108 million; total liquidity was NOK 109 million including available credit facilities.
- Private placement raised gross NOK 144.5 million, including NOK 73.2 million via receivables conversion, settling across Q2–Q3.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley monthly data: As of mid-August, Apple (AAPL.US) App Store net revenue declined by 0.6% year-on-year, turning negative for the first time in four years
According to a report by Morgan Stanley, based on monthly tracking data, the net revenue of the Apple App Store as of mid-August has declined year-on-year by 0.6% for the month, marking the first negative year-on-year growth in four years.
South Korea's semiconductor boom spreads tax revenue dividends, plans to establish a fund exceeding 100 trillion won to support youth and AI investments
South Korea plans to establish a chip profit fund to support youth and artificial intelligence investment.
